Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities

SALT LAKE CITY, TORONTO & MONTRÉAL (May 8, 2023) – Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica and Valence.  “Recursion has pioneered the massive, parallel generation of -omics data with […]

Cyclica teams up with Uruguay national research agency, ANII, to enhance scientific innovation

09  March  2023, Toronto, Canada and Montevideo, Uruguay – Cyclica Inc. (“Cyclica”), a neo-biotech that is unlocking the protein universe to discover the medicines of tomorrow, and the National Research and Innovation Agency (“Agencia Nacional de Investigación e Innovación” or ANII”), a Uruguayan government agency that funds and promotes research and innovation initiatives,  announce a […]

Cyclica and SK Chemicals announce agreement to co-develop novel therapeutics

Cyclica and SK Chemicals logos

Toronto, Canada and Seongnam-si, South Korea – Cyclica Inc. (“Cyclica”), a neo-biotech that is unlocking the protein universe to discover the medicines of tomorrow, and SK Chemicals Co., Ltd. (“SK Chemicals”), a global leader in total healthcare providing diagnostic, therapeutic and prophylactic solutions, today announced an AI-driven drug discovery and development partnership to develop therapies […]

Cyclica named as one of BioSpace’s ‘femtech companies to keep an eye on’

In the article ‘Progress Flickers in Women’s Healthcare as Femtech Builds Traction’, BioSpace named Cyclica among one of the “femtech companies to keep an eye on”. Written by Gail Dutton, this article includes an interview with Cyclica’s CEO and co-founder, Naheed Kurji, who discusses Cyclica’s goal to develop non-hormonal contraceptive options. Read the full story […]